Difference between revisions of "Stub"
Jump to navigation
Jump to search
m |
|||
| Line 1: | Line 1: | ||
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the [[Ontology]]. | Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the [[Ontology]]. | ||
{{TOC limit|limit=2}} | {{TOC limit|limit=2}} | ||
| − | == | + | ==CE & Thalidomide== |
{| class="wikitable" style="float:right; margin-left: 5px;" | {| class="wikitable" style="float:right; margin-left: 5px;" | ||
|- | |- | ||
|[[#top|back to top]] | |[[#top|back to top]] | ||
|} | |} | ||
| + | CE & Thalidomide: '''<u>C</u>'''arboplatin, '''<u>E</u>'''toposide, Thalidomide | ||
===Regimen=== | ===Regimen=== | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
Revision as of 01:54, 30 July 2020
Regimens that have not proven to be superior to a standard-of-care comparison and are thus unlikely to be expanded upon. This page is primarily to drive the Ontology.
CE & Thalidomide
| back to top |
CE & Thalidomide: Carboplatin, Etoposide, Thalidomide
Regimen
Chemotherapy
Targeted therapy
Ixabepilone & Bevacizumab
| back to top |
Regimen
Chemotherapy
Targeted therapy
TG+Bev
| back to top |
TG+Bev: Taxotere (Docetaxel), Gemcitabine, Bevacizumab
Regimen
Chemotherapy
Targeted therapy
TX+Bev
| back to top |
TX+Bev: Taxotere (Docetaxel), Xeloda (Capecitabine), Bevacizumab